Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
Cambridge, MA – June 28, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of Paul Brannelly as Chief Financial Officer. Mr. Brannelly is a corporate finance veteran, having raised over $1.4 billion in debt and equity throughout his career, and most recently served as Executive Vice President, Chief Financial Officer of Collegium Pharmaceutical, Inc.
“Paul brings more than 20 years of senior public and private company development and financial management experience as an executive in the biopharma industry and insights from Paul will be invaluable as we leverage our understanding of stress support pathways to bring paradigm-changing therapies to patients,” said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “We are thrilled to welcome Paul to our team.”
“I am excited to join Ribon Therapeutics as the company advances its proprietary BEACON+ platform and pipeline of therapeutics targeting stress support pathways, including its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors,” said Mr. Brannelly. “I look forward to working with the team to strategically advance the business.”
Throughout his tenure at Collegium Pharmaceutical, Inc., Mr. Brannelly played a significant role in directing financial strategy, budgeting and forecasting while also overseeing human resources, information technology and investor relations functions through their transition to a public company. Earlier, Mr. Brannelly served as Senior Vice President, Finance and Administration, Treasurer at Karyopharm Therapeutics Inc., where he was critical in managing the company’s finance, legal, accounting, facilities and public and investor relations functions through its transition to a public company. Prior to this role, Mr. Brannelly served as Vice President, Finance, Treasurer and Secretary at Verastem, Inc., and was Chief Financial Officer at the Longwood Fund, a venture capital firm aimed at investing in, managing and building healthcare companies, where he set up the financial and operational infrastructure following the closing of its first fund and eventually served as a finance executive at two of its startup companies, including Verastem, Inc. and OvaScience, Inc. Mr. Brannelly also served as Vice President, Finance at Sirtris Pharmaceuticals, Inc., a biopharmaceutical company which GlaxoSmithKline plc purchased for $720 million in 2008. Mr. Brannelly started his career in healthcare at Dyax Corporation and subsequently moved on to positions of increasing responsibility at CombinatoRx Inc. Mr. Brannelly graduated from the University of Massachusetts at Amherst with a B.B.A. in Accounting and was a Certified Public Accountant.
About Ribon Therapeutics
Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.